Cancer-associated fibroblasts undergoing neoadjuvant chemotherapy suppress rectal cancer revealed by single-cell and spatial transcriptomics

Cell Rep Med. 2023 Oct 17;4(10):101231. doi: 10.1016/j.xcrm.2023.101231.

Abstract

Neoadjuvant chemotherapy (NAC) for rectal cancer (RC) shows promising clinical response. The modulation of the tumor microenvironment (TME) by NAC and its association with therapeutic response remain unclear. Here, we use single-cell RNA sequencing and spatial transcriptome sequencing to examine the cell dynamics in 29 patients with RC, who are sampled pairwise before and after treatment. We construct a high-resolution cellular dynamic landscape remodeled by NAC and their associations with therapeutic response. NAC markedly reshapes the populations of cancer-associated fibroblasts (CAFs), which is strongly associated with therapeutic response. The remodeled CAF subsets regulate the TME through spatial recruitment and crosstalk to activate immunity and suppress tumor progression through multiple cytokines, including CXCL12, SLIT2, and DCN. In contrast, the epithelial-mesenchymal transition of malignant cells is upregulated by CAF_FAP through MIR4435-2HG induction, resulting in worse outcomes. Our study demonstrates that NAC inhibits tumor progression and modulates the TME by remodeling CAFs.

Keywords: cancer-associated fibroblast; cell-cell interaction; neoadjuvant chemotherapy; rectal cancer; remodelling; single-cell RNA sequencing; spatial transcriptome sequencing; suppress; therapeutic response; tumor microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cancer-Associated Fibroblasts* / pathology
  • Cell Proliferation
  • Humans
  • Neoadjuvant Therapy
  • Rectal Neoplasms* / drug therapy
  • Rectal Neoplasms* / genetics
  • Rectal Neoplasms* / pathology
  • Transcriptome / genetics
  • Tumor Microenvironment / genetics